Erratum of Guidelines for the drug treatment of rheumatoid arthritis

ERRATUM

Erratum of Guidelines for the drug treatment of rheumatoid arthritis

Licia Maria Henrique da Mota^I,*; Bóris Afonso Cruz^I; Claiton Viegas Brenol^I; Ivânio Alves Pereira^I; Lucila Stange Rezende-Fronza^I; Manoel Barros Bertolo^I; Max Vitor Carioca Freitas^I; Nilzio Antônio da Silva^I; Paulo Louzada-Junior^I; Rina Dalva Neubarth Giorgi^I; Rodrigo Aires Corrêa Lima^I; Wanderley Marques Bernardo^II; Geraldo da Rocha Castelar Pinheiro^I

^ISociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil

^IIAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil

In the original article, "Guidelines for the drug treatment of rheumatoid arthritis" (Rev Bras Reumatol 2013;53(2):158-183), where it reads:

Guidelines for the drug treatment of rheumatoid arthritis

Sociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology)

Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brazil

Participants

Licia Maria Henrique da Mota*, Bóris Afonso Cruz, Claiton Viegas Brenol, Ivânio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Vitor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgio, Rodrigo Aires Corrêa Lima, Wanderley Marques Bernardo, Geraldo da Rocha Castelar Pinheiro

It should read:

Guidelines for the drug treatment of rheumatoid arthritis

Licia Maria Henrique da Mota^a,*, Bóris Afonso Cruz^a, Claiton Viegas Brenol^a, Ivânio Alves Pereira^a, Lucila Stange Rezende-Fronza^a, Manoel Barros Bertolo^a, Max Vitor Carioca Freitas^a, Nilzio Antônio da Silva^a, Paulo Louzada-Junior^a, Rina Dalva Neubarth Giorgi^a, Rodrigo Aires Corrêa Lima^a, Wanderley Marques Bernardo^b, Geraldo da Rocha Castelar Pinheiro^a

^aSociedade Brasileira de Reumatologia (Brazilian Society of Rheumatology), São Paulo, SP, Brazil ^bAssociação Médica Brasileira (Brazilian Medical Association), São Paulo, SP, Brazil

At page 169, where it reads:

RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etarnecept (50 mg SC every two weeks), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).

it should reald:

RA patients can be treated with anti-TNF biologic DMARDs, including adalimumab (40 mg SC every two weeks), certolizumab (400 mg SC every two weeks at weeks 0, 2 and 4 and 200 mg every two weeks thereafter or 400 mg every four weeks, or monthly), etarnecept (50 mg SC weekly), golimumab (50 SC every four weeks or monthly), or infliximab (3 mg/kg IV at weeks 0, 2 and 6 and every 8 weeks thereafter).

At page 172, table 5 [Portuguese edition only], where it reads:

It should read:

Publication Dates

• Publication in this collection
  16 Sept 2013
• Date of issue
  June 2013